Navigation Links
Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
Date:3/20/2008

development and commercialization of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. The company's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products in the United States include: PROVIGIL(R) (modafinil) Tablets [C-IV], FENTORA(R) (fentanyl buccal tablet) [C-II], TRISENOX(R) (arsenic trioxide) injection, TREANDA, AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), VIVITROL(R) (naltrexone for extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products, including the results of any clinical programs with respect to TREANDA or the timing or approval of any current or future filings for regulatory approval of TREANDA or other Cephalon Oncology compounds; interpretation of clinical results, particularly with respect to the TREANDA clinical trials; manufacturing development and capabilities; market prospect
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements
2. Cephalons 2007 Results Exceed Full Year Sales and Earnings Guidance
3. Cephalon General Counsel John E. Osborn to Resign Position
4. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
5. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
6. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
7. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
8. Cephalon Submits Supplemental New Drug Application for FENTORA
9. Cephalon Announces Strong Third Quarter Financial Results
10. Cephalon Quarterly Conference Call Invitation
11. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2008)...SSAUGA, ON, Dec. 5 /PRNewswire-FirstCall/ - YM Bio...YMBA), an oncology company that identifies, develo...patients worldwide, today reported that Oncoscienc...,s subsidiary, CIMYM BioSciences Inc., has withdra...y (EMEA) for marketing authorization of nimotuzuma...
(Date:12/4/2008)...IEGO, Dec. 4 Favrille, I...ds.com, Inc. ("MMR"), a health,information compan...c Personal,Health Records (PHRs), announced today... closing of their definitive merger agreement have...m/cgi-bin/prnh/20080404/LAF521LOGO ) , "We ...
(Date:12/4/2008)...ership will accelerate research of potential vacci...and GAITHERSBURG, Md., Dec. 4 The ...ofit global health organization PATH announced tod...mic influenza vaccine. PATH will initially invest ...n early-stage development of a H5N1 virus-like par...
(Date:12/4/2008)...YSVILLE, Pa., Dec. 4 Ray...cer of Met-Pro Corporation (NYSE: MPR ), announce...their meeting on December 3, 2008, declared a quar... 12, 2009 to shareholders of record at the close o...presents a 9.1% increase over the same period last...
Breaking Biology Technology:YM BIOSCIENCES PROVIDES EU REGULATORY UPDATE 2YM BIOSCIENCES PROVIDES EU REGULATORY UPDATE 3Favrille and MyMedicalRecords.com, Inc. Obtain Shareholder Approval to Move Forward With Merger 2Favrille and MyMedicalRecords.com, Inc. Obtain Shareholder Approval to Move Forward With Merger 3Favrille and MyMedicalRecords.com, Inc. Obtain Shareholder Approval to Move Forward With Merger 4Favrille and MyMedicalRecords.com, Inc. Obtain Shareholder Approval to Move Forward With Merger 5Lentigen Corporation and PATH Announce Partnership on Innovative Vaccine for Pandemic Influenza 2Lentigen Corporation and PATH Announce Partnership on Innovative Vaccine for Pandemic Influenza 3Met-Pro Corporation Declares Quarterly Dividend 2
...gy data indicates that the lead cancer drug candid...t two important preconditions set by the Food and...tients. , ,The data, which was presented at the an...er Research , demonstrates the drug, QBI-139, can ...fe doses, the company announced. , ,Quintessence, ...
...ormation technology projects largely are the resul... inadequate collaboration between the Department o...cording to a long-awaited report from the state L...ch was a full year in the making, was ordered afte...hnology projects in several state agencies, includ...
...tate Division of Enterprise Technology is promis...contained in a recently released audit of state in...administrator of the DET since late February, said... in the audit report. Among them is the suggestion... this year to the Joint Legislative Audit Committ...
...ing innovation, most businesses don,t have large r...Hewlett-Packard does, but that didn,t prevent a v...tely held companies. Kristin Pugh, who is HP,s dir...sed small businesses to get comfortable with a han...lop the beta versions of products. , ,Pugh was her...
Other Biology Technology:Quintessence Biosciences advances cancer drug 2Technology audit rips poor planning and oversight 2Technology audit rips poor planning and oversight 3Technology audit rips poor planning and oversight 4State technology chief endorses IT audit recommendations 2State technology chief endorses IT audit recommendations 3Hewlett-Packard exec offers innovative counsel 2Hewlett-Packard exec offers innovative counsel 3
(Date:12/3/2008)...first 5-year forest inventory report for Oregon,s ...ublic: Oregon,s Forest Resources, 2001-2005: Five-...e are some key findings from the report:, , Ore...alf of Oregon,s total land area of 61 million acre... particularly near urban areas. The rate of conver...
(Date:12/3/2008)...f Oceanography at UC San Diego returning from rese...nted details of vibrant sea life and ecosystems in...of new species and marine animals previously never...urveys at unexplored depths, have revealed disturb...that human impacts have stretched down deeply in t...
(Date:12/3/2008)...ective gene into mouse blood cells, scientists at ...ted sickle cell disease pathology. In their studie...wed essentially no difference from normal mice. Al...ne therapy to humans presents significant technica...l become an important treatment for the disease. ,...
(Date:12/3/2008)...how a technique using lasers could be employed to ...aign supports one of the main objectives of the ca...E (Advanced Space Carbon and climate Observation o...Explorer missions that has just completed assessme...r five, will be presented to the science community...
Breaking Biology News(10 mins):Forest inventories in Oregon include more than trees 2Forest inventories in Oregon include more than trees 3Expeditions reveal gulf of California's deep sea secrets, as well as human imprints 2Expeditions reveal gulf of California's deep sea secrets, as well as human imprints 3Expeditions reveal gulf of California's deep sea secrets, as well as human imprints 4Gene therapy corrects sickle cell disease in laboratory study 2Gene therapy corrects sickle cell disease in laboratory study 3ESA tests laser to measure atmospheric carbon dioxide 2ESA tests laser to measure atmospheric carbon dioxide 3Research May Help Predict Preeclampsia 27479 1Research May Help Predict Preeclampsia 27479 2Research May Help Predict Preeclampsia 27479 3Research May Help Predict Preeclampsia 27479 4US Oncologys Innovent Oncology Division Announces First Agreement Between Rocky Mountain Cancer Centers and Colorado Public Employees Retirement Assoc 27476 1US Oncologys Innovent Oncology Division Announces First Agreement Between Rocky Mountain Cancer Centers and Colorado Public Employees Retirement Assoc 27476 2The Most Ordinary Things Can Cause the Most Extraordinary Eye Injuries Says the Oklahoma Academy of Ophthalmology 27472 1The Most Ordinary Things Can Cause the Most Extraordinary Eye Injuries Says the Oklahoma Academy of Ophthalmology 27472 2The Most Ordinary Things Can Cause the Most Extraordinary Eye Injuries Says the Oklahoma Academy of Ophthalmology 27472 3The Most Ordinary Things Can Cause the Most Extraordinary Eye Injuries Says the Oklahoma Academy of Ophthalmology 27472 4Caltech engineers build firast ever multi input plug and play synthetic RNA device 5440 1Caltech engineers build firast ever multi input plug and play synthetic RNA device 5440 2
... much detail one remembers of an event depends on ...d to "package" the memory. , The research may help... of an experience such as a car accident, and yet ...erience. , In experiments using functional magn... able to view what happened in the brains of subje...
...bstance that will make it possible for scientists ...micals in a faster, less expensive way. , In a let...Nature, a team led by professors Amir Hoveyda and ...tment said they had found a first-of-its-kind cata...ul steps from the process of synthesizing certain ...
...n shown to suppress the growth of tumor cells in t...GF-beta during the later stages of the disease are...an breast cancer samples and mice, which appears o...he January print issue of the Journal of Clinical ...n of one component of the TGF-beta receptor, T-bet...
...dings of the National Academy of Science (PNAS), r... Medicine generated a mouse model exhibiting reduc...hers found that the transcription factor LITAF (Li...ontrols inflammation through a completely differen...transcriptional regulator. , Drugs regulating ...
Other Biology News:Memories: It's all in the packaging, scientists say 2BC catalyst discovery promises faster, cheaper drug production 2
...rokinase (rEK) is a highly purified preparation of...erine protease which recognizes the identical clea...and has similar enzymatic activity (1). Novagen&'s...ld the highest activity available, and is qualifie...
Angiotensin Converting Enzyme [Porcine Kidney, ACE, Peptidyl-dipeptidase A]
The bench-top stand comfortably holds up to 6 Finnpipette Digital single- and multichannel pipettes. The crossbars are made of a grippy material to keep the pipettes firmly in place. Individual shelf
...ase-2A (PPase-2A) is a serine/threonine phosphatas...ted as the heterodimer of 60kDa (A) and 36kDa (C) ...e a-subunit of phosphorylase kinase. With its 3638...e specificity and may play a regulatory role in DN...
Biology Products: